search
Calendar
Make a Payment
Schedule an Appointment
Patient Forms
Patient Portal

Resources

Academic Cancer Care

Ironwood Cancer & Research Centers are committed to the advancement of medical knowledge and patient care. Medical research has and continues to transform the practice of medicine resulting in a high quality of care we enjoy today. We believe that by supporting clinical research today, we are helping build the future of medicine and the profound developments that are sure to come. We have an active and expanding clinical research program.

We have a comprehensive team of physician investigators, research nurses, clinical research coordinators, research assistants and regulatory specialist serving all our offices. This allows us to provide the option for our eligible patients to the latest therapies and treatments.  If you are interested in participating in a clinical trial, please talk to your physician or call our research department at 480-398-7671.  Learn more about participating in a clinical trial here.

Current Studies at Ironwood Cancer & Research Centers

Filters
Filters
Cancer Type
Show (42)
Cancel

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/​Metastatic Disease (FourLight-3)

ClinicalTrials.gov ID NCT06760637 

Protocol ID PF-07220060

Sponsor Pfizer

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

ClinicalTrials.gov ID NCT02609776

Protocol ID JNJ-61186372COR3002

Sponsor Janssen Pharmaceutical

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

ClinicalTrials.gov ID NCT06562543

Protocol number TAK-113-4002

Sponsor Takeda

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ClinicalTrials.gov ID NCT06588478

Protocol number J2N-MC-JZNX

Sponsor Loxo Oncology, Inc.

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

ClinicalTrials.gov ID NCT06246916

Protocol number R3767-ONC-22122

Sponsor Regeneron Pharmaceuticals, Inc.

Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

ClinicalTrials.gov ID NCT06697301

Protocol number EIK1001-006

Sponsor Eikon Therapeutics

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

ClinicalTrials.gov ID NCT06246110

Protocol number EIK1001-005

Sponsor Eikon Therapeutics

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/​HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

ClinicalTrials.gov ID NCT06312176

Protocol number MK2870-010

Sponsor Merck Sharp & Dohme LLC

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

ClinicalTrials.gov ID NCT06377852

Protocol number 00075309

Sponsor American Society of Clinical Oncology

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

ClinicalTrials.gov ID NCT06252649

Protocol number AMG 20210081

Sponsor Amgen

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)- ENROLLMENT ON HOLD 

ClinicalTrials.gov ID NCT06120140

Protocol number Janssen_COCOON

Sponsor Janssen Research & Development, LLC

ENROLLMENT ON HOLD 

 

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

ClinicalTrials.gov ID NCT06393374

Protocol number MK-2870-012

Sponsor Merck Sharp & Dohme LLC

 

A Study of Camizestrant in ER+/​HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

ClinicalTrials.gov ID NCT05774951

Protocol number D8531C00002

Sponsor Astra Zeneca

   

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)

ClinicalTrials.gov ID NCT05059444

Protocol number 02-MX-003

Sponsor Guardant Health, Inc.

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

ClinicalTrials.gov ID NCT05215340

Protocol number DS1062-A-U304

Sponsor Daiichi-Sankyo

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

ClinicalTrials.gov ID NCT05555732

Protocol number DS1062-A-U303

Sponsor Daiichi-Sankyo

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

ClinicalTrials.gov ID NCT05211895

Protocol number PACIFIC-8 D9075C00001

Sponsor Astra Zeneca

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

ClinicalTrials.gov ID NCT06003231

Protocol number SGNDV-005

Sponsor Seagen Inc.

*Cohort Closed at this time*

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC

ClinicalTrials.gov ID NCT04928846

Protocol number M18-868

Sponsor AbbVie

 

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

ClinicalTrials.gov ID NCT05199818

Protocol number LP-CT-PALO-202101

Sponsor Xiamen LP Pharmaceutical Co., Ltd

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01)

ClinicalTrials.gov ID NCT06120491

Protocol number D973C00001

Sponsor Astra Zeneca

pixel